Hereditary Angioedema Therapeutic Market size is projected to reach US$ 14.19 Bn at the end of the forecast period at a CAGR of 16.79%. Increasing cases of hereditary angioedema (HAE) globally is a mainly driving the Hereditary Angioedema Therapeutic market. According to the National Organization for Rare Disorders (NORD), about 1-9 people per 100,000 population are affected by the condition. The actual number of individuals with the condition are significantly higher due to under-reporting and misdiagnosis. The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.To know about the Research Methodology :- Request Free Sample Report In 2022, there were approximately 422,700 prevalent cases of hereditary angioedema worldwide, and forecasts that number to increase to xx K prevalent cases by 2029. This increasing cases of hereditary angioedema (HAE) is driving the hereditary angioedema (HAE) therapeutics market. Lack of awareness about HAE International (HAE), an international hereditary angioedema patient organization, is a major reason for misdiagnosis, which in turn, leads to inadequate treatment being provided to patients. The hereditary angioedema market is segmented into such as drug class, route of administration, by treatment type, and by region. By drug class market is further segmented into four other categories such as kallikrein inhibitor, selective bradykinin B2 receptor antagonist, C1 esterase inhibitor, and others. C1 esterase inhibitor segment is expected to exhibit highest market share at a CAGR of xx% over forecast period. By geography, hereditary angioedema market is segmented into APAC, North America, Europe, MEA& Africa and Latin America. North America accounted for a leading share in the market in terms of revenue in 2022 owing to new product launches by major players, better reimbursement scenario, and a well-developed healthcare infrastructure. Growing patient awareness levels, coupled with launch of novel therapies for hereditary angioedema management, is expected to drive the market in the region. Key players operating in hereditary angioedema market are BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pharming Group N.V., CSL Limited, Shire Plc., Attune Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., and KalVista Pharmaceuticals, Inc. These players are entering into distribution agreements in order to increase their market share boost and their presence across different geographies. The objective of the report is to present comprehensive analysis of hereditary angioedema market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding hereditary angioedema market dynamics, structure by analysing the market segments, and project the global critical communication market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the hereditary angioedema market make the report investor’s guide.
Hereditary Angioedema Therapeutic Market Scope: Inquire before buying
Global Hereditary Angioedema Therapeutic Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 4.78 Bn. Forecast Period 2023 to 2029 CAGR: 16.79% Market Size in 2029: US $ 14.19 Bn. Segments Covered: by Drug Class C1-esterase inhibitor Bradykinin B2 receptor antagonist Kallikrein inhibitor Others by Treatment Type Prophylaxis On-demand by Route of Administration Intravenous Subcutaneous Oral Hereditary Angioedema Therapeutic Market by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Hereditary Angioedema Therapeutic Market Key players
1.BioCryst Pharmaceuticals, Inc. 2.Ionis Pharmaceuticals, Inc. 3.Pharming Group N.V. 4.CSL Limited 5.Shire Plc 6.Attune Pharmaceuticals, Inc. 7.Adverum Biotechnologies, Inc. 8.KalVista Pharmaceuticals, Inc. 9.Novartis AG 10.CENTOGENE AG 11.Sanofi 12.Takeda Pharmaceutical Company Limited 13.Cipla Frequently Asked Questions: 1. Which region has the largest share in Global Hereditary Angioedema Therapeutic Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Hereditary Angioedema Therapeutic Market? Ans: The Global Hereditary Angioedema Therapeutic Market is growing at a CAGR of 16.79% during forecasting period 2023-2029. 3. What is scope of the Global Hereditary Angioedema Therapeutic market report? Ans: Global Hereditary Angioedema Therapeutic Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Hereditary Angioedema Therapeutic market? Ans: The important key players in the Global Hereditary Angioedema Therapeutic Market are – BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pharming Group N.V., CSL Limited, Shire Plc, Attune Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, Inc., Novartis AG, CENTOGENE AG, Sanofi, Takeda Pharmaceutical Company Limited, and Cipla 5. What is the study period of this market? Ans: The Global Hereditary Angioedema Therapeutic Market is studied from 2022 to 2029.
Hereditary Angioedema Therapeutic Market
1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.2. Secondary data 2.3.3. Secondary Sources 2.3.4. Primary Research 2.3.5. Data from Primary Sources 2.3.6. Breakdown of Primary Sources 3. Executive Summary: Global Hereditary Angioedema Therapeutic Market, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Hereditary Angioedema Therapeutic Market Analysis and Forecast 6.1. Global Hereditary Angioedema Therapeutic Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Hereditary Angioedema Therapeutic Market Analysis and Forecast, By Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Hereditary Angioedema Therapeutic Market Value Share Analysis, By Drug Class 7.4. Global Hereditary Angioedema Therapeutic Market Size (US$ Bn) Forecast, By Drug Class 7.5. Global Hereditary Angioedema Therapeutic Market Analysis, By Drug Class 7.6. Global Hereditary Angioedema Therapeutic Market Attractiveness Analysis, By Drug Class 8. Global Hereditary Angioedema Therapeutic Market Analysis and Forecast, By Treatment Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Hereditary Angioedema Therapeutic Market Value Share Analysis, By Treatment Type 8.4. Global Hereditary Angioedema Therapeutic Market Size (US$ Bn) Forecast, By Treatment Type 8.5. Global Hereditary Angioedema Therapeutic Market Analysis, By Treatment Type 8.6. Global Hereditary Angioedema Therapeutic Market Attractiveness Analysis, By Treatment Type 9. Global Hereditary Angioedema Therapeutic Market Analysis and Forecast, by Route of Administration 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Hereditary Angioedema Therapeutic Market Value Share Analysis, by Route of Administration 9.4. Global Hereditary Angioedema Therapeutic Market Size (US$ Bn) Forecast, by Route of Administration 9.5. Global Hereditary Angioedema Therapeutic Market Analysis, by Route of Administration 9.6. Global Hereditary Angioedema Therapeutic Market Attractiveness Analysis, by Route of Administration 10. Global Hereditary Angioedema Therapeutic Market Analysis, by Region 10.1. Global Hereditary Angioedema Therapeutic Market Value Share Analysis, by Region 10.2. Global Hereditary Angioedema Therapeutic Market Size (US$ Bn) Forecast, by Region 10.3. Global Hereditary Angioedema Therapeutic Market Attractiveness Analysis, by Region 11. North America Hereditary Angioedema Therapeutic Market Analysis 11.1. Key Findings 11.2. North America Hereditary Angioedema Therapeutic Market Overview 11.3. North America Hereditary Angioedema Therapeutic Market Value Share Analysis, By Drug Class 11.4. North America Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 11.4.1. C1-esterase inhibitor 11.4.2. Bradykinin B2 receptor antagonist 11.4.3. Kallikrein inhibitor 11.4.4. Others 11.5. North America Hereditary Angioedema Therapeutic Market Value Share Analysis, By Treatment Type 11.6. North America Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 11.6.1. Prophylaxis 11.6.2. On-demand 11.7. North America Hereditary Angioedema Therapeutic Market Value Share Analysis, by Route of Administration 11.8. North America Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 11.8.1. Intravenous 11.8.2. Subcutaneous 11.8.3. Oral 11.9. North America Hereditary Angioedema Therapeutic Market Value Share Analysis, by Country 11.10. North America Hereditary Angioedema Therapeutic Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Hereditary Angioedema Therapeutic Market Analysis, by Country 11.12. U.S. Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 11.12.1. C1-esterase inhibitor 11.12.2. Bradykinin B2 receptor antagonist 11.12.3. Kallikrein inhibitor 11.12.4. Others 11.13. U.S. Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 11.13.1. Prophylaxis 11.13.2. On-demand 11.14. U.S. Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 11.14.1. Intravenous 11.14.2. Subcutaneous 11.14.3. Oral 11.15. Canada Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 11.15.1. C1-esterase inhibitor 11.15.2. Bradykinin B2 receptor antagonist 11.15.3. Kallikrein inhibitor 11.15.4. Others 11.16. Canada Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 11.16.1. Prophylaxis 11.16.2. On-demand 11.17. Canada Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 11.17.1. Intravenous 11.17.2. Subcutaneous 11.17.3. Oral 11.18. North America Hereditary Angioedema Therapeutic Market Attractiveness Analysis 11.18.1. By Drug Class 11.18.2. By Treatment Type 11.18.3. By Route of Administration 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Development 12. Europe Hereditary Angioedema Therapeutic Market Analysis 12.1. Key Findings 12.2. Europe Hereditary Angioedema Therapeutic Market Overview 12.3. Europe Hereditary Angioedema Therapeutic Market Value Share Analysis, By Drug Class 12.4. Europe Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 12.4.1. C1-esterase inhibitor 12.4.2. Bradykinin B2 receptor antagonist 12.4.3. Kallikrein inhibitor 12.4.4. Others 12.5. Europe Hereditary Angioedema Therapeutic Market Value Share Analysis, By Treatment Type 12.6. Europe Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 12.6.1. Prophylaxis 12.6.2. On-demand 12.7. Europe Hereditary Angioedema Therapeutic Market Value Share Analysis, by Route of Administration 12.8. Europe Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 12.8.1. Intravenous 12.8.2. Subcutaneous 12.8.3. Oral 12.9. Europe Hereditary Angioedema Therapeutic Market Value Share Analysis, by Country 12.10. Europe Hereditary Angioedema Therapeutic Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Hereditary Angioedema Therapeutic Market Analysis, by Country 12.12. Germany Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 12.12.1. C1-esterase inhibitor 12.12.2. Bradykinin B2 receptor antagonist 12.12.3. Kallikrein inhibitor 12.12.4. Others 12.13. Germany Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 12.13.1. Prophylaxis 12.13.2. On-demand 12.14. Germany Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 12.14.1. Intravenous 12.14.2. Subcutaneous 12.14.3. Oral 12.15. U.K. Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 12.15.1. C1-esterase inhibitor 12.15.2. Bradykinin B2 receptor antagonist 12.15.3. Kallikrein inhibitor 12.15.4. Others 12.16. U.K. Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 12.16.1. Prophylaxis 12.16.2. On-demand 12.17. U.K. Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 12.17.1. Intravenous 12.17.2. Subcutaneous 12.17.3. Oral 12.18. France Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 12.18.1. C1-esterase inhibitor 12.18.2. Bradykinin B2 receptor antagonist 12.18.3. Kallikrein inhibitor 12.18.4. Others 12.19. France Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 12.19.1. Prophylaxis 12.19.2. On-demand 12.20. France Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 12.20.1. Intravenous 12.20.2. Subcutaneous 12.20.3. Oral 12.21. Italy Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 12.21.1. C1-esterase inhibitor 12.21.2. Bradykinin B2 receptor antagonist 12.21.3. Kallikrein inhibitor 12.21.4. Others 12.22. Italy Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 12.22.1. Prophylaxis 12.22.2. On-demand 12.23. Italy Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 12.23.1. Intravenous 12.23.2. Subcutaneous 12.23.3. Oral 12.24. Spain Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 12.24.1. C1-esterase inhibitor 12.24.2. Bradykinin B2 receptor antagonist 12.24.3. Kallikrein inhibitor 12.24.4. Others 12.25. Spain Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 12.25.1. Prophylaxis 12.25.2. On-demand 12.26. Spain Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 12.26.1. Intravenous 12.26.2. Subcutaneous 12.26.3. Oral 12.27. Rest of Europe Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 12.27.1. C1-esterase inhibitor 12.27.2. Bradykinin B2 receptor antagonist 12.27.3. Kallikrein inhibitor 12.27.4. Others 12.28. Rest of Europe Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 12.28.1. Prophylaxis 12.28.2. On-demand 12.29. Rest of Europe Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 12.29.1. Intravenous 12.29.2. Subcutaneous 12.29.3. Oral 12.30. Europe Hereditary Angioedema Therapeutic Market Attractiveness Analysis 12.30.1. By Drug Class 12.30.2. By Treatment Type 12.30.3. By Route of Administration 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Development 13. Asia Pacific Hereditary Angioedema Therapeutic Market Analysis 13.1. Key Findings 13.2. Asia Pacific Hereditary Angioedema Therapeutic Market Overview 13.3. Asia Pacific Hereditary Angioedema Therapeutic Market Value Share Analysis, By Drug Class 13.4. Asia Pacific Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 13.4.1. C1-esterase inhibitor 13.4.2. Bradykinin B2 receptor antagonist 13.4.3. Kallikrein inhibitor 13.4.4. Others 13.5. Asia Pacific Hereditary Angioedema Therapeutic Market Value Share Analysis, By Treatment Type 13.6. Asia Pacific Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 13.6.1. Prophylaxis 13.6.2. On-demand 13.7. Asia Pacific Hereditary Angioedema Therapeutic Market Value Share Analysis, by Route of Administration 13.8. Asia Pacific Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 13.8.1. Intravenous 13.8.2. Subcutaneous 13.8.3. Oral 13.9. Asia Pacific Hereditary Angioedema Therapeutic Market Value Share Analysis, by Country 13.10. Asia Pacific Hereditary Angioedema Therapeutic Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Hereditary Angioedema Therapeutic Market Analysis, by Country 13.12. China Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 13.12.1. C1-esterase inhibitor 13.12.2. Bradykinin B2 receptor antagonist 13.12.3. Kallikrein inhibitor 13.12.4. Others 13.13. China Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 13.13.1. Prophylaxis 13.13.2. On-demand 13.14. China Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 13.14.1. Intravenous 13.14.2. Subcutaneous 13.14.3. Oral 13.15. India Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 13.15.1. C1-esterase inhibitor 13.15.2. Bradykinin B2 receptor antagonist 13.15.3. Kallikrein inhibitor 13.15.4. Others 13.16. India Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 13.16.1. Prophylaxis 13.16.2. On-demand 13.17. India Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 13.17.1. Intravenous 13.17.2. Subcutaneous 13.17.3. Oral 13.18. Japan Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 13.18.1. C1-esterase inhibitor 13.18.2. Bradykinin B2 receptor antagonist 13.18.3. Kallikrein inhibitor 13.18.4. Others 13.19. Japan Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 13.19.1. Prophylaxis 13.19.2. On-demand 13.20. Japan Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 13.20.1. Intravenous 13.20.2. Subcutaneous 13.20.3. Oral 13.21. ASEAN Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 13.21.1. C1-esterase inhibitor 13.21.2. Bradykinin B2 receptor antagonist 13.21.3. Kallikrein inhibitor 13.21.4. Others 13.22. ASEAN Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 13.22.1. Prophylaxis 13.22.2. On-demand 13.23. ASEAN Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 13.23.1. Intravenous 13.23.2. Subcutaneous 13.23.3. Oral 13.24. Rest of Asia Pacific Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 13.24.1. C1-esterase inhibitor 13.24.2. Bradykinin B2 receptor antagonist 13.24.3. Kallikrein inhibitor 13.24.4. Others 13.25. Rest of Asia Pacific Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 13.25.1. Prophylaxis 13.25.2. On-demand 13.26. Rest of Asia Pacific Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 13.26.1. Intravenous 13.26.2. Subcutaneous 13.26.3. Oral 13.27. Asia Pacific Hereditary Angioedema Therapeutic Market Attractiveness Analysis 13.27.1. By Drug Class 13.27.2. By Treatment Type 13.27.3. By Route of Administration 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Development 14. Middle East & Africa Hereditary Angioedema Therapeutic Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Hereditary Angioedema Therapeutic Market Overview 14.3. Middle East & Africa Hereditary Angioedema Therapeutic Market Value Share Analysis, By Drug Class 14.4. Middle East & Africa Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 14.4.1. C1-esterase inhibitor 14.4.2. Bradykinin B2 receptor antagonist 14.4.3. Kallikrein inhibitor 14.4.4. Others 14.5. Middle East & Africa Hereditary Angioedema Therapeutic Market Value Share Analysis, By Treatment Type 14.6. Middle East & Africa Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 14.6.1. Prophylaxis 14.6.2. On-demand 14.7. Middle East & Africa Hereditary Angioedema Therapeutic Market Value Share Analysis, by Route of Administration 14.8. Middle East & Africa Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 14.8.1. Intravenous 14.8.2. Subcutaneous 14.8.3. Oral 14.9. Middle East & Africa Hereditary Angioedema Therapeutic Market Value Share Analysis, by Country 14.10. Middle East & Africa Hereditary Angioedema Therapeutic Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Hereditary Angioedema Therapeutic Market Analysis, by Country 14.12. GCC Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 14.12.1. C1-esterase inhibitor 14.12.2. Bradykinin B2 receptor antagonist 14.12.3. Kallikrein inhibitor 14.12.4. Others 14.13. GCC Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 14.13.1. Prophylaxis 14.13.2. On-demand 14.14. GCC Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 14.14.1. Intravenous 14.14.2. Subcutaneous 14.14.3. Oral 14.15. South Africa Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 14.15.1. C1-esterase inhibitor 14.15.2. Bradykinin B2 receptor antagonist 14.15.3. Kallikrein inhibitor 14.15.4. Others 14.16. South Africa Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 14.16.1. Prophylaxis 14.16.2. On-demand 14.17. South Africa Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 14.17.1. Intravenous 14.17.2. Subcutaneous 14.17.3. Oral 14.18. Rest of Middle East & Africa Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 14.18.1. C1-esterase inhibitor 14.18.2. Bradykinin B2 receptor antagonist 14.18.3. Kallikrein inhibitor 14.18.4. Others 14.19. Rest of Middle East & Africa Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 14.19.1. Prophylaxis 14.19.2. On-demand 14.20. Rest of Middle East & Africa Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 14.20.1. Intravenous 14.20.2. Subcutaneous 14.20.3. Oral 14.21. Middle East & Africa Hereditary Angioedema Therapeutic Market Attractiveness Analysis 14.21.1. By Drug Class 14.21.2. By Treatment Type 14.21.3. By Route of Administration 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Development 15. South America Hereditary Angioedema Therapeutic Market Analysis 15.1. Key Findings 15.2. South America Hereditary Angioedema Therapeutic Market Overview 15.3. South America Hereditary Angioedema Therapeutic Market Value Share Analysis, By Drug Class 15.4. South America Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 15.4.1. C1-esterase inhibitor 15.4.2. Bradykinin B2 receptor antagonist 15.4.3. Kallikrein inhibitor 15.4.4. Others 15.5. South America Hereditary Angioedema Therapeutic Market Value Share Analysis, By Treatment Type 15.6. South America Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 15.6.1. Prophylaxis 15.6.2. On-demand 15.7. South America Hereditary Angioedema Therapeutic Market Value Share Analysis, by Route of Administration 15.8. South America Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 15.8.1. Intravenous 15.8.2. Subcutaneous 15.8.3. Oral 15.9. South America Hereditary Angioedema Therapeutic Market Value Share Analysis, by Country 15.10. South America Hereditary Angioedema Therapeutic Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Hereditary Angioedema Therapeutic Market Analysis, by Country 15.12. Brazil Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 15.12.1. C1-esterase inhibitor 15.12.2. Bradykinin B2 receptor antagonist 15.12.3. Kallikrein inhibitor 15.12.4. Others 15.13. Brazil Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 15.13.1. Prophylaxis 15.13.2. On-demand 15.14. Brazil Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 15.14.1. Intravenous 15.14.2. Subcutaneous 15.14.3. Oral 15.15. Mexico Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 15.15.1. C1-esterase inhibitor 15.15.2. Bradykinin B2 receptor antagonist 15.15.3. Kallikrein inhibitor 15.15.4. Others 15.16. Mexico Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 15.16.1. Prophylaxis 15.16.2. On-demand 15.17. Mexico Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 15.17.1. Intravenous 15.17.2. Subcutaneous 15.17.3. Oral 15.18. Rest of South America Hereditary Angioedema Therapeutic Market Forecast, By Drug Class 15.18.1. C1-esterase inhibitor 15.18.2. Bradykinin B2 receptor antagonist 15.18.3. Kallikrein inhibitor 15.18.4. Others 15.19. Rest of South America Hereditary Angioedema Therapeutic Market Forecast, By Treatment Type 15.19.1. Prophylaxis 15.19.2. On-demand 15.20. Rest of South America Hereditary Angioedema Therapeutic Market Forecast, by Route of Administration 15.20.1. Intravenous 15.20.2. Subcutaneous 15.20.3. Oral 15.21. South America Hereditary Angioedema Therapeutic Market Attractiveness Analysis 15.21.1. By Drug Class 15.21.2. By Treatment Type 15.21.3. By Route of Administration 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Development 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. BioCryst Pharmaceuticals, Inc. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Company Footprint 16.3.2. Ionis Pharmaceuticals, Inc. 16.3.3. Pharming Group N.V. 16.3.4. CSL Limited 16.3.5. Shire Plc 16.3.6. Attune Pharmaceuticals, Inc. 16.3.7. Adverum Biotechnologies, Inc. 16.3.8. Novartis AG 16.3.9. CENTOGENE AG 16.3.10. Sanofi 16.3.11. Takeda Pharmaceutical Company Limited 16.3.12. Cipla 17. Primary Key Insights